Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical...
18 insider purchases on record · latest filing 2025-08-05.
Insiders have also filed 33 sale transactions at PRME.